

RECEIVED
CENTRAL FAX CENTER

NOV 19 2004

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/607,521
	Filing Date	June 26, 2003
	First Named Inventor	Stefan SCHÄFER et al.
	Art Unit	1614
	Examiner Name	Hénley III, Raymond J.
	Attorney Docket Number	DEAV2002/0044 US NP
Total Number of Pages in This Submission	9	

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.62 or 1.53		
Remarks Enclosures: 1) Amendment Pursuant to 37 CFR 1.21(c) and Response After Final Pursuant to 37 CFR 1.116 - 8 pgs. 2) Return postcard		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature	<i>Lawrence L. Martin</i>		
Printed name	Lawrence L. Martin		
Date	November 19, 2004	Reg. No.	46,902

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 ; Total No. of Pages Transmitted: 9)			
Signature	<i>Bonnie Stein</i>		
Typed or printed name	Bonnie Stein	Date	November 19, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOV. 19. 2004 3:04PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 9920 P. 2

NOV 19 2004

PATENT

Docket No.: DEAV2002/0044 US NP
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Schafer et al.

Examiner: Raymond J Henley III

Serial No.: 10/607,521

Art Unit: 1614

Filed: 06/26/2003

Title: Use of Vasopeptidase Inhibitors in the
Treatment of Metabolic Diseases,
Nephropathy and Advanced Glycation
End-Product Associated Diseases

CERTIFICATE OF TRANSMISSION
I hereby certify that this correspondence is being transmitted
via facsimile to the Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, at 703-872-9306
on
Date of Deposit: November 19, 2004
Printed Name of Person Signing Certificate: Ronnie Surin
Signature: Ronnie Surin

AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 (c)
AND RESPONSE AFTER FINAL PURSUANT TO 37 C.F.R. § 1.116

Box Non-Fee Amendment

Commissioner for Patents

Washington, D.C. 20231

Sir:

This is in response to the outstanding Final Office Action, dated September 14, 2004, for which a response is due by December 14, 2004, in the above-identified patent application. Applicants respectfully request entry of the following remarks and amendments. Applicants request reconsideration and withdrawal of all outstanding rejections in light of the aforesaid remarks and amendments.